Press Releases

JUPITER, Fla., Aug. 13 /PRNewswire-FirstCall/ — Dyadic International, Inc. (“Dyadic”) (Pink Sheets: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the second quarter ended June 30, 2010. The financial information contained in this press release should be read in conjunction with the financial statements and related footnotes which have been posted on the Pink Sheets website atwww.pinksheets.comand on Dyadic’s website atwww.dyadic.com.

Dyadic’s President and Chief Executive Officer, Mark Emalfarb, stated, “During the second quarter, we made significant progress in positioning Dyadic for future long-term growth by continuing to enhance our C1 technology and hiring key personnel and advisors to unlock the value of that technology primarily in the areas of biofuels and chemicals. We also laid the foundation to apply our C1 technology to the development and commercialization of biopharmaceuticals. All of this is now being pursued without the overhanging risk, cost and distraction of protracted stockholder litigation which we have put behind us.”

Recent Company Highlights

In 2010, Dyadic has made significant progress in the following areas:

General

  1. Achieved final resolution of the stockholder class action lawsuit. Research & Development

  2. Continued to improve the efficiency and performance of our enzymes for use in creating new industrial enzyme products and enhancing our current product offerings in the areas of animal feed, pulp and paper, starch and alcohol, food and brewing, textiles and alternative fuels.

  1. Continued to enhance our C1 technology in collaboration with Scripps Florida, a division of the Scripps Research Institute, and Dyadic Netherlands, for greater applicability in producing higher enzyme yields at lower cost for the benefit of our licensing and research partners.

  1. Initiated several provisional patent applications on genes and the enzymes they encode which resulted from ongoing research programs.

  2. Dedicated a greater portion of Dyadic’s research and development capabilities to revenue generating collaborations including the use of our C1 technology for expressing proteins and enzymes in higher quantities from the genes provided by third parties.

Biofuels

  1. Engaged the Abraham Group LLC and former U.S. Energy Secretary, Spencer Abraham, as a strategic advisor to implement an international initiative designed to identify potential licensees and strategic partners for Dyadic among major international companies who have demonstrated strong interest in alternative energy and to assist in consummating those transactions.

  2. Initiated and continued ongoing discussions with several major companies for the potential license of Dyadic’s C1 technology for the development and commercialization of biofuels and biochemicals.

Biopharmaceuticals

  1. Entered into a term sheet for a potential exclusive outlicense of C1 technology for biopharmaceutical applications to EnGen Bio, Inc.

  1. Continued discussions with numerous companies and investors regarding the potential funding of EnGen Bio as well as ongoing negotiations with a third party to conduct proof-of-concept scientific studies to validate the C1 technology’s ability to meet certain protein expression levels as a condition of such funding.

Industrial Enzymes

  1. Improved product margins from 20% to 33% for the year to date.

  1. Continued discussions and negotiations with several companies for the potential license of Dyadic’s C1 technology for animal feed and food applications.

  1. Strengthened Dyadic’s leadership team through the hiring of a Vice President Sales & Marketing.

  1. Introduced and launched two new enzymes for the textiles market.

  1. Increased production capacity.

Financial Results

Total revenue for the second quarter ended June 30, 2010 decreased to approximately $2.2 million compared to approximately $11.9 million for the second quarter ended June 30, 2009. Total revenue for the six months ended June 30, 2010 decreased to approximately $4.2 million compared to approximately $16.9 million for the six months ended June 30, 2009. The decrease in total revenue for the three month period ended June 30, 2010 as compared to the three month period ended June 30, 2009 was due to a decrease in licensing revenue. The decrease in total revenue for the six month period ended June 30, 2010 as compared to the six month period ended June 30, 2009 was due to a decrease in research and development revenue and licensing revenue as described below.

Net product related revenue for the second quarter remained essentially flat at approximately $1.7 million. Net product related revenue for the six months ended June 30, 2010 increased to approximately $3.6 million from approximately $3.2 million for the same period a year ago.

Research and development revenue for the second quarter ended June 30, 2010 increased to approximately $465,000 compared to approximately $396,000 for the second quarter ended June 30, 2009. Research and development revenue for the six months ended June 30, 2010 decreased to approximately $554,000 compared to approximately $3.9 million for the six months ended June 30, 2009. The decrease in research and development revenue for the six months ended June 30, 2010 compared to the six months ended June 30, 2009 was due to research and development revenue recognized in the first quarter of 2009 of $ 3.3 million received from Abengoa Bioenergy R&D, Inc. pursuant to a securities purchase agreement between Dyadic and Abengoa.

There was no license fee revenue for the second quarter ended June 30, 2010 compared to license fee revenue of approximately $9.8 million for the second quarter ended June 30, 2009. License fee revenue for the six months ended June 30, 2010 decreased to approximately $32,000 compared to approximately $9.8 million for the six months ended June 30, 2009. The decrease in license fee revenue for the three and six month periods ended June 30, 2010 compared to the three and six month periods ended June 30, 2009 was due to licensee fee revenue recognized in the second quarter of 2009 of approximately $9.8 million related to license fees received from Codexis, Inc. pursuant to the non-exclusive license agreement between Codexis and Dyadic.

Gross margins for net product related revenue, exclusive of shipping and other costs, increased to 33% for the six months ended June 30, 2010 compared to 20% for the six months ended June 30, 2009 as a result of the continued focus on more profitable product lines and improvements to inventory management and overall operating efficiencies.

Net loss for the second quarter ended June 30, 2010 was approximately $1.4 million, or $(0.05) per basic and diluted share, compared to net income of approximately $8.6 million, or $0.29 per basic and $0.26 per diluted share for the second quarter ended June 30, 2009. Net loss for the six months ended June 30, 2010 was approximately $2.5 million, or $(0.08) per basic and diluted share, respectively, compared to net income of approximately $10.9 million, or $0.36 per basic and $0.33 per diluted share, for the six months ended June 30, 2009.

At June 30, 2010, cash and cash equivalents were approximately $4.0 million compared to approximately $8.4 million at December 31, 2009. A significant portion of the decrease in cash and cash equivalents since the end of last year was due to costs incurred and payments by Dyadic to resolve the stockholder class action lawsuit.

Conference Call

A conference call to discuss Dyadic’s 2010 second quarter financial results is scheduled for 11:00 a.m. Eastern Time on Friday, August 13, 2010. The conference call may be accessed by dialing 888-724-9504 (domestic) or 913-312-0951 (international) five to ten minutes prior to start time and providing the passcode 4931751.

ABOUT DYADIC

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries. Please visit Dyadic’s website atwww.dyadic.com.

Dyadic makes financial disclosures through the Pink OTC Markets Disclosure and News Service which offers free information on the Pink Sheets website ( www.pinksheets.com) concerning issuers listed on the Pink Sheets over-the-counter market. Investors can access and download Dyadic’s financial reports and other announcements that Dyadic makes through the Pink Sheets website. Dyadic will also continue providing updates through regular press releases as appropriate.

CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Six Months Ended June 30,

Three Months Ended June 30,

2010

2009

2010

2009

(Unaudited)

(Unaudited)

(Unaudited)

(Unaudited)

Revenue:

Product Related Revenue, Net

$ 3,618,937

$ 3,210,964

$ 1,739,792

$ 1,754,765

License Fee Revenue

32,000

9,750,000

9,750,000

Research and Development Revenue

553,575

3,920,801

465,340

396,388

Total Revenue

4,204,512

16,881,765

2,205,132

11,901,153

Cost of Goods Sold:

3,090,979

2,975,786

1,485,650

1,819,789

Gross Profit

1,113,533

13,905,979

719,482

10,081,364

Expenses:

General and Administrative

2,634,142

1,845,313

1,274,476

1,022,056

Sales and Marketing

472,596

455,457

245,863

184,440

Research and Development

648,634

624,502

362,595

241,300

Foreign Currency Exchange Losses, Net

260,543

50,252

227,246

18,770

Total Expenses

4,015,915

2,975,524

2,110,180

1,466,566

Income (Loss) from Operations

(2,902,382)

10,930,455

(1,390,698)

8,614,798

Other Income (Expense)

Interest Income

36,012

70,995

14,741

48,116

Interest Expense

(65,066)

(109,866)

(31,687)

(43,316)

Gain on Reduction of Accrued Stockholder

Litigation

410,000

Other

243

243

(1,198)

Total Other Income (Expense)

381,189

(38,871)

(16,703)

3,602

Net Income (Loss)

$ (2,521,193)

$ 10,891,584

$ (1,407,401)

$ 8,618,400

Net Income (Loss) per Common Share

Basic

$

(0.08)

$

0.36

$

(0.05)

$

0.29

Diluted

$

(0.08)

$

0.33

$

(0.05)

$

0.26

Weighted Average Common Shares Used in

Calculating Net Income (Loss) Per Share:

Basic

30,906,706

30,027,962

30,985,745

30,002,830

Diluted

30,906,706

32,936,567

30,985,745

33,218,934

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

June 30,

December 31,

2010

2009

ASSETS

(Unaudited)

Current Assets:

Cash and Cash Equivalents

$ 3,964,486

$

8,419,934

Restricted Cash

270,540

316,129

Accounts Receivable, Net

1,626,781

1,376,034

Inventory, Net

2,754,425

2,820,381

Prepaid Expenses and Other Current Assets

302,867

420,654

Total Current Assets

8,919,099

13,353,132

Fixed Assets, Net

845,858

839,639

Intangible Assets, Net

147,383

148,167

Other Assets

16,930

16,930

$

9,929,270

$

14,357,868

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:

Accounts Payable

$ 1,882,804

$

1,949,038

Accrued Expenses

279,133

713,163

Accrued Stockholder Litigation

1,340,000

3,250,000

Accrued Interest Payable to Stockholder

33,750

59,838

Note Payable to Stockholder

1,424,941

1,424,941

Income Taxes Payable

2,005

767

Total Current Liabilities

4,962,633

7,397,747

COMMITMENTS AND CONTINGENCIES

Stockholders’ Equity:

Preferred Stock, $.0001 Par Value:

Authorized Shares – 5,000,000; None Issued and Outstanding

Common Stock, $.001 par value,

Authorized Shares – 100,000,000; Issued and

31,007

30,614

Outstanding – 31,006,995 and 30,613,995, Respectively

Additional Paid-In Capital

76,617,987

76,075,899

Stock to Be Issued

9,117

23,887

Accumulated Deficit

(71,691,474)

(69,170,279)

4,966,637

6,960,121

$

9,929,270

$

14,357,868

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Six Months Ended June 30,

2010

2009

(Unaudited)

(Unaudited)

Operating Activities

Net Income (Loss)

$ (2,521,193)

$ 10,891,584

Adjustments to Reconcile Net Income (Loss) to Net Cash

Provided By (Used In) Operating Activities:

Depreciation and Amortization of Fixed Assets

151,096

87,682

Amortization of Intangible and Other Assets

7,068

7,067

Reduction of Allowance for Doubtful Accounts

(132,030)

Reduction of Inventory Reserve

(333,795)

(490,414)

Compensation Expense on Stock Option Grants

425,032

58,025

Stock Issued for Financial Services

63,000

Stock Issued for Rent

5,000

Gain on Reduction of Accrued Stockholder Litigation

(410,000)

Changes in Operating Assets and Liabilities:

Accounts Receivable

(118,717)

(9,247)

Inventory

399,751

1,125,490

Prepaid Expenses and Other Current Assets

117,787

22,105

Other Assets

27,604

Accounts Payable

(66,234)

(319,621)

Accrued Expenses

(434,030)

(74,011)

Accrued Interest Payable to Stockholder

(26,088)

(167,154)

Accrued Stockholder Litigation

(1,500,000)

Deferred Research and Development Obligations

(3,082,863)

Income Taxes Payable

1,238

(5,584)

Net Cash Provided By (Used In) Operating Activities

(4,377,115)

8,075,663

Investing Activities

Purchases of Fixed Assets

(157,315)

(12,402)

Patent Costs

(6,284)

Restricted Cash

45,589

1,197

Net Cash (Used In) Investing Activities

(118,010)

(11,205)

Financing Activities

Repayment of Note Payable to Stockholder

(1,000,000)

Proceeds from Stock Warrant Exercises

16,876

Proceeds from Stock Option Exercises

22,801

Net Cash Provided By (Used In) Financing Activities

39,677

(1,000,000)

Net Increase (Decrease) in Cash and Cash Equivalents

(4,455,448)

7,064,458

Cash and Cash Equivalents at Beginning of Period

8,419,934

2,826,542

Cash and Cash Equivalents at End of Period

$

3,964,486

$

9,891,000

Supplemental Cash Flow Information:

Cash Paid for Interest

$

91,154

$

277,020

CONTACT:

Dyadic International, Inc.

Michael J. Faby

Vice President Finance

Phone: 561-743-8333

Email: mfaby@dyadic.com